Skip to main navigation Skip to search Skip to main content

Re: Endpoints for Clinical Trials in Primary Hyperoxaluria

  • D. S. Milliner
  • , T. L. McGregor
  • , A. Thompson
  • , B. Dehmel
  • , J. Knight
  • , R. Rosskamp
  • , M. Blank
  • , S. Yang
  • , S. Fargue
  • , G. Rumsby
  • , J. Groothoff
  • , M. Allain
  • , M. West
  • , K. Hollander
  • , W. T. Lowther
  • , J. C. Lieske
  • , Dean G. Assimos
  • Mayo Clinic Rochester, MN
  • Alnylam Pharmaceuticals
  • OxThera AB, Stockholm, Sweden
  • University of Alabama at Birmingham
  • United States Food and Drug Administration
  • University College London Hospitals, London, UK
  • Amsterdam UMC - University of Amsterdam
  • American Society of Nephrology
  • Oxalosis and Hyperoxaluria Foundation, New Paltz, New York, USA
  • Wake Forest University

Research output: Contribution to journalComment/Letter to the editorAcademic

18 Downloads (Pure)
Original languageEnglish
Pages (from-to)613
JournalJournal of urology
Volume204
Issue number3
DOIs
Publication statusPublished - 1 Sept 2020

Cite this